CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies

Blood

Volumn 130, Issue 3, 2017, Pages 297-309

  Al Sayed, Mohamad F ^a   Ruckstuhl, Carla A ^a   Hilmenyuk, Tamara ^a   Claus, Christina ^a,c   Bourquin, Jean Pierre ^b   Bornhauser, Beat C ^b   Radpour, Ramin ^a   Riether, Carsten ^a   Ochsenbein, Adrian F ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c Roche Innovation Center Zurich   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD70 ANTIGEN; GAMMA INTERFERON; PROTEIN KINASE B; LIGAND;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; B LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DEFICIENCY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; MORTALITY; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REGULATORY T LYMPHOCYTE; SURVIVAL ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE; XENOGRAFT;

ANIMALS; ANTIGENS, CD27; ANTIGENS, CD70; B-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; HUMANS; IMMUNOLOGIC SURVEILLANCE; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, KNOCKOUT; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HETEROLOGOUS;

EID: 85026304618     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-12-756585     Document Type: Article

References (69)

1. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol. 2005;17(3):275-281.
2. van Oosterwijk MF, Juwana H, Arens R, et al. CD27-CD70 interactions sensitise naive CD41 T cells for IL-12-induced Th1 cell development. Int Immunol. 2007;19(6):713-718.
3. Welten SP, Redeker A, Franken KL, et al. CD27-CD70 costimulation controls T cell immunity during acute and persistent cytomegalovirus infection. J Virol. 2013; 87(12):6851-6865.
4. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol. 2000;1(5):433-440.
5. Takeda K, Oshima H, Hayakawa Y, et al. CD27-mediated activation of murine NK cells. J Immunol. 2000;164(4):1741-1745.
6. Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. Immunol Today. 2000;21(5):204-206.
7. Nagumo H, Agematsu K. Synergistic augmentative effect of interleukin-10 and CD27/ CD70 interactions on B-cell immunoglobulin synthesis. Immunology. 1998;94(3):388-394.
8. van Oers MH, Pals ST, Evers LM, et al. Expression and release of CD27 in human B-cell malignancies. Blood. 1993;82(11):3430-3436.
9. Nilsson A, de Milito A, Mowafi F, et al. Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. Exp Hematol. 2005; 33(12):1500-1507.
10. Dong HY, Shahsafaei A, Dorfman DM. CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells. Leuk Lymphoma. 2002;43(9):1855-1858.
11. Deeb SJ, D’Souza RC, Cox J, Schmidt-Supprian M, Mann M. Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles. Mol Cell Proteomics. 2012;11(5):77-89.
12. Goodwin RG, Alderson MR, Smith CA, et al. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell. 1993;73(3):447-456.
13. Loenen WA, De Vries E, Gravestein LA, Hintzen RQ, Van Lier RA, Borst J. The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis. Eur J Immunol. 1992;22(2):447-455.
14. Purdue MP, Lan Q, Bagni R, et al. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res. 2011;71(14):4898-4907.
15. Bowman MR, Crimmins MA, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S. The cloning of CD70 and its identification as the ligand for CD27. J Immunol. 1994;152(4):1756-1761.
16. Oshima H, Nakano H, Nohara C, et al. Characterization of murine CD70 by molecular cloning and mAb. Int Immunol. 1998;10(4):517-526.
17. Tesselaar K, Xiao Y, Arens R, et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol. 2003;170(1):33-40.
18. Yang FC, Agematsu K, Nakazawa T, et al. CD27/ CD70 interaction directly induces natural killer cell killing activity. Immunology. 1996;88(2):289-293.
19. Matter M, Odermatt B, Yagita H, Nuoffer JM, Ochsenbein AF. Elimination of chronic viral infection by blocking CD27 signaling. J Exp Med. 2006;203(9):2145-2155.
20. Tesselaar K, Arens R, van Schijndel GM, et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol. 2003;4(1):49-54.
21. Beishuizen CR, Kragten NA, Boon L, Nolte MA, van Lier RA, van Gisbergen KP. Chronic CD70-driven costimulation impairs IgG responses by instructing T cells to inhibit germinal center B cell formation through FasL-Fas interactions. J Immunol. 2009;183(10):6442-6451.
22. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. CD701 non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD41CD25 T cells. Blood. 2007;110(7):2537-2544.
23. Baba M, Okamoto M, Hamasaki T, et al. Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-cell lines and adult T-cell leukemia cells. J Virol. 2008; 82(8):3843-3852.
24. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood. 1995;85(12): 3556-3565.
25. Lens SM, Drillenburg P, den Drijver BF, et al. Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol. 1999; 106(2):491-503.
26. Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K, Schubert J. CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol. 2005;173(6):2150-2153.
27. Chahlavi A, Rayman P, Richmond AL, et al. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res. 2005;65(12):5428-5438.
28. Held-Feindt J, Mentlein R. CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors. Int J Cancer. 2002;98(3):352-356.
29. Agathanggelou A, Niedobitek G, Chen R, Nicholls J, Yin W, Young LS. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol. 1995;147(4):1152-1160.
30. Hishima T, Fukayama M, Hayashi Y, et al. CD70 expression in thymic carcinoma. Am J Surg Pathol. 2000;24(5):742-746.
31. Ryan MC, Kostner H, Gordon KA, et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer. 2010;103(5): 676-684.
32. Petrau C, Cornic M, Bertrand P, et al. CD70: A Potential Target in Breast Cancer? J Cancer. 2014;5(9):761-764.
33. Liu N, Sheng X, Liu Y, Zhang X, Yu J. Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas. Onco Targets Ther. 2013;6:615-619.
34. Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev. 2009; 229(1):216-231.
35. Wajant H, Scheurich P. Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int J Biochem Cell Biol. 2001; 33(1):19-32.
36. Erlichman B, Howard OM. CD27 signals through PKC in human B cell lymphomas. Cytokine. 1999; 11(7):476-484.
37. Arens R, Nolte MA, Tesselaar K, et al. Signaling through CD70 regulates B cell activation and IgG production. J Immunol. 2004;173(6):3901-3908.
38. Yoshino K, Kishibe K, Nagato T, et al. Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27. Br J Haematol. 2013;160(3):331-342.
39. García P, De Heredia AB, Bellón T, et al. Signalling via CD70, a member of the TNF family, regulates T cell functions. J Leukoc Biol. 2004; 76(1):263-270.
40. Orengo AM, Cantoni C, Neglia F, Biassoni R, Ferrini S. Reciprocal expression of CD70 and of its receptor, CD27, in human long term-activated T and natural killer (NK) cells: inverse regulation by cytokines and role in induction of cytotoxicity. Clin Exp Immunol. 1997;107(3):608-613.
41. Schmitz M, Breithaupt P, Scheidegger N, et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood. 2011;118(7): 1854-1864.
42. Matter M, Pavelic V, Pinschewer DD, et al. Decreased tumor surveillance after adoptive T-cell therapy. Cancer Res. 2007;67(15): 7467-7476.
43. Claus C, Riether C, Schürch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res. 2012; 72(14):3664-3676.
44. Ochsenbein AF, Klenerman P, Karrer U, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA. 1999;96(5):2233-2238.
45. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 2001; 411(6841):1058-1064.
46. Mombaerts P, Mizoguchi E, Ljunggren HG, et al. Peripheral lymphoid development and function in TCR mutant mice. Int Immunol. 1994;6(7): 1061-1070.
47. Kuka M, Munitic I, Giardino Torchia ML, Ashwell JD. CD70 is downregulated by interaction with CD27. J Immunol. 2013;191(5):2282-2289.
48. Dave SS, Fu K, Wright GW, et al; Lymphoma/ Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431-2442.
49. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21): 7252-7259.
50. Kmiecik J, Poli A, Brons NH, et al. Elevated CD31 and CD81 tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. 2013; 264(1-2):71-83.
51. Fend F, Quintanilla-Martínez L. Assessing the prognostic impact of immune cell infiltrates in follicular lymphoma. Haematologica. 2014;99(4): 599-602.
52. Silence K, Dreier T, Moshir M, et al. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. MAbs. 2014;6(2): 523-532.
53. Riether C, Schürch CM, Flury C, et al. Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. Sci Transl Med. 2015; 7(298):298ra119.
54. Zhang B, Kracker S, Yasuda T, et al. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell. 2012;148(4):739-751.
55. Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16(3):405-408.
56. Afshar-Sterle S, Zotos D, Bernard NJ, et al. Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat Med. 2014;20(3):283-290.
57. Bolitho P, Street SE, Westwood JA, et al. Perforin-mediated suppression of B-cell lymphoma. Proc Natl Acad Sci USA. 2009;106(8): 2723-2728.
58. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000;192(5): 755-760.
59. Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood. 2004;103(11):4251-4258.
60. Stopeck AT, Gessner A, Miller TP, et al. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res. 2000;6(10):3904-3909.
61. Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of b2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011;20(6):728-740.
62. Lanier LL. Natural killer cell receptor signaling. Curr Opin Immunol. 2003;15(3):308-314.
63. Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol. 2004;22:405-429.
64. Salzer E, Daschkey S, Choo S, et al. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica. 2013;98(3):473-478.
65. Abolhassani H, Edwards ES, Ikinciogullari A, et al. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med. 2017; 214(1):91-106.
66. Izawa K, Martin E, Soudais C, et al. Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. J Exp Med. 2017; 214(1):73-89.
67. Bonehill A, Tuyaerts S, Van Nuffel AM, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther. 2008; 16(6):1170-1180.
68. Thomas LJ, He LZ, Marsh H, Keler T. Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity. OncoImmunology. 2014; 3(1):e27255.
69. Schürch C, Riether C, Matter MS, Tzankov A, Ochsenbein AF. CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. J Clin Invest. 2012;122(2): 624-638.